13th International Congress
13th International Congress

News Release

Monday, June 8, 2009

Media Contact:
Elizabeth Laur, elaur@movementdisorders.org
+1 414-276-2145 (MDS Secretariat)
MDS 13th International Congress Press Room (June 7-11):
Le Palais des Congres de Paris,
Room 212/213, Level 2, Hall Maillot, TEL: +33 (0)1 40 68 63 74

Study Suggests Ineffectiveness of Minocycline as Treatment for Huntington's Disease

PARIS - A study investigating the usefulness of minocycline as treatment for Huntington's Disease (HD) was presented today at The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders.

The phase II clinical trial, led by Merit Cudkowicz, MD, and colleagues at Massachusetts General Hospital in Boston, examines minocycline as a treatment for HD among 114 research participants, 27 of which were given placebo. The progression of HD was measured by change in Total Functional Capacity (TFC) and Unified Huntington's Disease Rating Scale (UHDRS) scores, both indicating ineffectiveness.

Overall, this study suggests that while minocycline at 200 mg/day was well tolerated and safe amongst participants over 18 months of treatment, further study of the drug as a treatment for HD is not necessary.

M. Flint Beal, MD, Neurologist in Chief at Weill Medical College of Cornell University, New York, states "I think that this is an important study since it suggests that minocycline is not worth while pursuing as a therapy for HD. These are outstanding investigators and the study is carefully done, and therefore the conclusions appear to be valid. Minocycline was recently shown to be detrimental in a study in ALS, and in a futility study in PD it did not appear promising. Overall the clinical studies of minocycline for treatment of neurodegenerative diseases do not seem promising."

Meeting attendees are gathered to learn the latest research findings and state-of-the-art treatment options for Movement Disorders, including Parkinson's disease. More than 3,900 physicians and medical professionals from 90 countries will be able to view over 1,700 scientific abstracts submitted by clinicians from around the world.

The Movement Disorder Society, an international society of over 3,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research.

For more information about The Movement Disorder Society, visit www.movementdisorders.org